As of June 21, 2025, Catalyst Biosciences Inc (CBIO) reports a Net Margin of -1038.04%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Catalyst Biosciences Inc's Net Margin
Over recent years, Catalyst Biosciences Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2022-12-31 | -1038.04% |
| 2021-12-31 | -1198.32% |
| 2020-12-31 | -268.45% |
| 2019-12-31 | -300600.00% |
| 2018-12-31 | -2113.73% |
This fluctuation highlights how Catalyst Biosciences Inc manages its overall profitability and cost control over time.
Comparing Catalyst Biosciences Inc's Net Margin to Peers
To better understand Catalyst Biosciences Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Catalyst Biosciences Inc (CBIO) | -1038.04% |
| Aptevo Therapeutics Inc (APVO) | 257.77% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
Compared to its competitors, Catalyst Biosciences Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.